Chronic prostatitis: the evidence says no single treatment works well

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition in men whose main features are pelvic pain and lower urinary tract symptoms, usually with no infection that anyone can find [s1]. The evidence is that no single treatment works well: the drugs prescribed most often — alpha-blockers, antibiotics and anti-inflammatories — each deliver only small, low-certainty improvements, while some non-drug options, notably acupuncture and shockwave therapy, actually have the firmer trial support [s1][s2].

A syndrome, not an infection

Despite the name, CP/CPPS is not the bacterial prostate infection the word "prostatitis" implies. It is a chronic pain syndrome, and its severity is tracked with a validated questionnaire, the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) [s1]. Cochrane's reviewers set the threshold for a change that matters to patients — the minimal clinically important difference — at a 25% fall in the baseline score, or a reduction of about six points [s1]. That six-point bar is the number to keep in mind, because most treatments fall short of it.

What the drug trials show

The pharmacological evidence is large but weak. A Cochrane review pooled 99 studies in 9,119 men across 16 types of drug treatment, and graded almost all of the evidence low or very low certainty [s1]. It also noted that 21 of the studies were funded by pharmaceutical companies [s1].

Taking the main classes in turn: alpha-blockers, across 18 trials, reduced the total NIH-CPSI score by a mean of 5.01 points versus placebo (95% confidence interval 7.41 to 2.61), an effect the reviewers rated very low certainty and one that sits just below the six-point threshold [s1]. Antibiotics, specifically quinolones, cut the score by 2.43 points (95% CI 4.72 to 0.15; low certainty) [s1]. Anti-inflammatories reduced it by 2.50 points (95% CI 3.74 to 1.26) and plant-based phytotherapy by 5.02 points (95% CI 6.81 to 3.23), both low certainty [s1]. Finasteride, a 5-alpha reductase inhibitor, reduced symptoms by 4.60 points in a single small trial rated moderate certainty [s1].

Two things stand out. Most of these average effects are at or below the six-point mark that defines a meaningful change, and the confidence intervals are wide [s1]. And alpha-blockers, the most-studied option, were also the class most clearly associated with side effects — dizziness and a drop in blood pressure on standing, with a risk ratio of 1.60 for such adverse events [s1]. That antibiotics help at all in a syndrome with no demonstrable infection is itself a caution against reaching for them reflexively [s1].

The non-drug options that hold up

The counterintuitive finding is that some of the strongest evidence is for treatments that are not drugs. A companion Cochrane review of non-pharmacological interventions pooled 38 studies in 3,290 men [s2]. Acupuncture, over three trials, produced a clinically meaningful reduction in symptoms compared with a sham procedure — a mean difference of 5.79 points on the NIH-CPSI (95% CI 7.32 to 4.26) — and the reviewers rated that evidence high certainty [s2]. Extracorporeal shockwave therapy performed similarly, cutting symptoms by 6.18 points versus control (95% CI 7.46 to 4.89), also high certainty, and it appeared to improve sexual function as well [s2].

Neither is a definitive cure, and the effects at longer follow-up are less certain [s2]. But it is notable that the two interventions carrying high-certainty evidence in this condition are a needle technique and a physical therapy, not a pill [s2].

What it adds up to

The take-home is a hard one for a condition that causes real suffering: there is no reliably effective single treatment for CP/CPPS, and the honest guidance most specialists now follow is to combine modest-benefit options tailored to a man's particular symptoms rather than to expect any one of them to fix the problem [s1][s2]. The urinary component overlaps with the far more common enlarged prostate, covered in our review of BPH treatment, and pelvic-floor approaches are discussed in our piece on pelvic-floor muscle training. Where pain is the dominant symptom, imaging such as prostate MRI is aimed at other diagnoses, not this one.

This article is informational and is not medical advice. Persistent pelvic pain or urinary symptoms should be assessed by a clinician.